FDA Approves Praluent for Children with Genetic Form of High Cholesterol.

The article focuses on the U.S. Food and Drug Administration (FDA) approval of Praluent (alirocumab) for children aged 8 and above with heterozygous familial hypercholesterolemia (HeFH), providing an treatment option for managing low-density lipoprotein (LDL) cholesterol levels in this population. Topics include the mechanism of Praluent, its wholesale acquisition cost, and the results of a phase 3 trial demonstrating its efficacy in reducing LDL-C levels with minimal adverse reactions.